Breaking News

ProBioGen, Nobelpharma Enter Mfg. Agreement for Vax Project

To leverage ProBioGen’s vaccine development platform consisting of its AGE1.CR.pIX suspension cell line and its high performance cell culture medium.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ProBioGen AG signed a service agreement for Nobelpharma’s vaccine project leveraging ProBioGen’s vaccine development platform consisting of its AGE1.CR.pIX suspension cell line and its high performance cell culture medium, for the propagation of Nobelpharma’s virus strain.   ProBioGen will apply state-of-the-art technologies to perform the upstream and downstream process development for Nobelpharma’s highly relevant vaccine for large scale manufacturing.   The duck cell line AGE1.CR.pI...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters